1433875-21-8

Basic information

• Product Name: ACT 080803
• Synonyms: ACT 080803;5-(4-Bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-ylamine
• CAS NO: 1433875-21-8
• Molecular Formula: C16H13Br2N5O2
• Molecular Weight: 467.11472
• Mol File: 1433875-21-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ACT 080803(CAS DataBase Reference)
• NIST Chemistry Reference: ACT 080803(1433875-21-8)
• EPA Substance Registry System: ACT 080803(1433875-21-8)

Safety Data

• Hazardous Substances Data: 1433875-21-8(Hazardous Substances Data)

Usage

Description

ACT 080803, also known as Despropylaminosulfonyl Macitentan, is an impurity of Macitentan (M105005). Macitentan is a dual, orally active endothelin receptor antagonist that is primarily used for the treatment of pulmonary arterial hypertension. ACT 080803 is a derivative of Macitentan, and its properties and applications may vary from the parent compound.

Uses

Used in Pharmaceutical Industry:
ACT 080803 is used as an impurity in the production of Macitentan (M105005) for the treatment of pulmonary arterial hypertension. It is important to monitor and control the levels of this impurity to ensure the safety and efficacy of the final drug product.
Additionally, as a derivative of Macitentan, ACT 080803 may have potential applications in research and development for understanding the structure-activity relationships of endothelin receptor antagonists. This could lead to the discovery of new therapeutic agents with improved properties or novel indications.
It is important to note that the uses of ACT 080803 are primarily related to its role as an impurity in the production of Macitentan. Further research may be required to explore its potential applications in other areas.

Upstream product

• 1393813-43-8 N‐[5‐(4‐bromophenyl)‐6‐[2‐hydroxyethoxy]‐4‐pyrimidinyl]‐N‐propylsulfamide 
• 1393813-42-7 N-5-(4-bromophenyl)-6-chloro-4-pyrimidinyl-N‘-propylsulfamide 
• 706811-25-8 5-(4-bromophenyl)-4,6-dihydroxypyrimidine 
• 149506-35-4 2-(4-bromophenyl)-malonic acid dimethyl ester 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 146533-41-7 5-(4-bromophenyl)-4,6-dichloropyrimidine 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 

Relevant articles and documents

Characterization of degradation products of macitentan under various stress conditions using liquid chromatography/mass spectrometry

Rationale: Stress testing of a drug candidate is an important step in the drug discovery and development process. The presence of degradation products in a drug affects the quality as well as the safety and efficacy of drug formulation. Hence, it is essential to develop an efficient analytical method which could be useful for the separation, identification and characterization of all possible degradation products (DPs) of a drug. Macitentan (MT) is an endothelin receptor antagonist (ERA) drug used to treat high blood pressure in the lungs. Comprehensive stress testing of MT was carried out as per ICH guidelines to understand the degradation profile of the drug. Methods: MT was subjected to various stress conditions such as acidic, basic, neutral hydrolysis, oxidation, photolysis and thermal conditions; and the resulting degradation products were investigated using liquid chromatography/diode-array detection/electrospray ionization high-resolution mass spectrometry (LC/DAD/ESI-HRMS) and tandem mass spectrometry (MS/MS) techniques. An efficient and simple ultra-high-performance liquid chromatography (UHPLC) method has been developed using an Accucore C18 column (4.6?×?150?mm, 2.6?μm) using a gradient elution of 5?mM ammonium formate and acetonitrile as mobile phases. Results: MT was found to degrade under acid and base hydrolysis stress conditions; whereas it was stable under oxidation, neutral hydrolysis, thermal and photolytic conditions. MT formed nine DPs (DP1 to DP9) and one DP (DP10) under acidic and basic hydrolytic conditions, respectively. All the degradation products (DP1 to DP10) were identified and characterized by LC/MS/MS in positive ion mode with accurate mass measurements. Conclusions: MT was found to be labile under hydrolytic conditions. The structures of the DPs were characterized by appropriate mechanisms. The proposed method can be effectively used for the characterization of MT and its DPs.

Method for synthesizing macitentan impurity standard substance

The invention discloses a method for synthesizing a macitentan impurity standard substance. The method comprises that macitentan as a raw material is hydrolyzed through inorganic base so that a crude product is obtained, and the crude product is refined to form a 5-(4-bromophenyl)-6-[2-[(5-bromopyrimidinyl)-2-oxo]ethoxy]-4-aminopyrimidine pure product. The impurity synthesis method provided by the invention utilizes cheap and easily available raw materials and has simple processes and a short preparation period. After standardization, product content is more than 99.0%. The macitentan impurity can be used as an impurity standard substance for the qualitative and quantitative research and detection of a macitentan raw material and its preparation impurity.